Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.58 |
| ▸ | TLR2 | O60603 | 2/20 | 0.57 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.57 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.57 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.56 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.55 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.55 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.55 |
| ▸ | RRM1 | P23921 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | GGT1 | P19440 | 1/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | FURIN | P09958 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.43 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28385127 | 1.00 | NOD1 (0.58) | NOD1TLR2SIRT6SIRT1SLC6A5 | |
| SCHEMBL31042212 | 1.00 | NOD1 (0.58) | NOD1TLR2SIRT6SIRT1SLC6A5 | |
| SCHEMBL2050730 | 1.00 | NOD1 (0.58) | NOD1TLR2SIRT6SIRT1SLC6A5 | |
| SCHEMBL31042213 | 1.00 | NOD1 (0.58) | NOD1TLR2SIRT6SIRT1SLC6A5 | |
| SCHEMBL31050906 | 1.00 | NOD1 (0.58) | NOD1TLR2SIRT6SIRT1SLC6A5 | |
| SCHEMBL285285 | 1.00 | NOD1 (0.58) | NOD1TLR2SIRT6SIRT1SLC6A5 | |
| SCHEMBL9791228 | 1.00 | NOD1 (0.58) | NOD1TLR2SIRT6SIRT1SLC6A5 | |
| SCHEMBL7460571 | 1.00 | NOD1 (0.58) | NOD1TLR2SIRT6SIRT1SLC6A5 | |
| SCHEMBL2701831 | 1.00 | NOD1 (0.58) | NOD1TLR2SIRT6SIRT1SLC6A5 | |
| SCHEMBL28461571 | 1.00 | NOD1 (0.58) | NOD1TLR2SIRT6SIRT1SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4226918-A1 | PHARMACEUTICAL SINGLE DOSAGE FORM FOR ORAL DELIVERY OF PEPTIDES | Majewski, Filip (PL) | 2023-08-16 | — | — | EP | claimed |
| US-20160339081-A1 | Peptide Pharmaceutical for Oral Delivery | UNIGENE LABORATORIES INC. | 2016-11-24 | — | — | US | claimed |
| EP-0162747-B1 | LYSINE ESTERS USED AS ABSORPTION ENHANCING AGENTS | MERCK & CO. INC. (US) | 1988-12-07 | — | — | EP | claimed |
| CN-115920000-B | Modulators of complement activity | RA制药公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20250073309-A1 | METHODS OF TREATMENT OF PEDIATRIC PUBERTY USING ORAL FORMULATIONS OF LEUPROLIDE | ENTERIS BIOPHARMA, INC. (US) | 2025-03-06 | — | — | US | disclosed |
| US-20250057771-A1 | ROOM TEMPERATURE STABLE ORAL CALCITONIN FORMULATION | PARK THERAPEUTICS INC (US) | 2025-02-20 | — | — | US | disclosed |
| CN-118695874-A | Cancer therapy with TLR7/8 agonists | 阿森迪斯药物肿瘤股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| US-11998640-B2 | Room temperature stable oral calcitonin formulation | PARK THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240059735-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-02-22 | — | — | US | disclosed |
| EP-4319790-A1 | METHODS OF TREATMENT OF PEDIATRIC PUBERTY USING ORAL FORMULATIONS OF LEUPROLIDE | Enteris BioPharma, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2004064758-A2 | IMPROVED ORAL DELIVERY OF PEPTIDES | UNIGENE LABORATORIES INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| US-6673574-B2 | PH LOWERING AGENT AND/OR PRTOEASE INHIBITOR AND AN ACID RESISTANT PROTECTIVE VEHICLE FOR TRANSPORT THROUGH THE STOMACH | UNIGENE LABORATORIES INC. | 2004-01-06 | — | — | US | disclosed |
| EP-1339431-A1 | IMPROVED ORAL DELIVERY OF PEPTIDES USING ENZYME-CLEAVABLE MEMBRANE TRANSLOCATORS | Unigene Laboratories, Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-20030118610-A1 | Oral delivery of peptides using enzyme-cleavable membrane translocators | UNIGENE LABORATORIES INC. | 2003-06-26 | — | — | US | disclosed |
| WO-2002043767-A1 | IMPROVED ORAL DELIVERY OF PEPTIDES USING ENZYME-CLEAVABLE MEMBRANE TRANSLOCATORS | UNIGENE LABORATORIES INC. (US) | 2002-06-06 | — | — | WO | disclosed |
| EP-0929270-A4 | ORAL PEPTIDE PHARMACEUTICAL PRODUCTS | UNIGENE LAB INC (US) | 2001-05-16 | — | — | EP | disclosed |
| US-6086918-A | RELEASING PEPTIDE ACTIVE AGENT, WITH PH LOWERING AGENT AND AN ABSORPTION ENHANCER INTO PATIENT'S INTESTINE THROUGH MOUTH AND STOMACH UNDER PROTECTION OF AN ACID RESISTANT VEHICLE WHICH PREVENTS CONTACT BETWEEN STOMACH PROTEASE AND PEPTIDE | UNIGENE LABORATORIES, INC. (US) | 2000-07-11 | — | — | US | disclosed |
| EP-0929270-A1 | ORAL PEPTIDE PHARMACEUTICAL PRODUCTS | Unigene Laboratories, Inc. (US) | 1999-07-21 | — | — | EP | disclosed |
| WO-1997033531-A1 | ORAL PEPTIDE PHARMACEUTICAL PRODUCTS | UNIGENE LABORATORIES, INC. (US) | 1997-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059735-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | MTPN, CKMT1A; CKMT1B, TFAM | NOD1 2495/4885TLR2 4609/4885SIRT6 2039/4885 |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | S100A10, SPG11, TMSB10 | NOD1 228/4885TLR2 2823/4885SIRT6 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.